IRIS
CASSANITI, IRENE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.264
AS - Asia 1.614
EU - Europa 1.462
SA - Sud America 291
AF - Africa 43
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 5.680
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.180
CN - Cina 507
SG - Singapore 491
RU - Federazione Russa 330
HK - Hong Kong 317
IT - Italia 266
BR - Brasile 244
DE - Germania 221
IE - Irlanda 221
FI - Finlandia 131
VN - Vietnam 98
GB - Regno Unito 91
CA - Canada 44
IN - India 41
JP - Giappone 39
PL - Polonia 35
FR - Francia 30
MX - Messico 30
ES - Italia 24
SE - Svezia 23
NL - Olanda 21
ZA - Sudafrica 21
BD - Bangladesh 19
TR - Turchia 19
AT - Austria 17
AR - Argentina 13
ID - Indonesia 13
IQ - Iraq 13
VE - Venezuela 12
BE - Belgio 9
LT - Lituania 9
CZ - Repubblica Ceca 7
CH - Svizzera 6
CL - Cile 6
IL - Israele 6
MA - Marocco 6
PK - Pakistan 6
EC - Ecuador 5
EG - Egitto 5
AE - Emirati Arabi Uniti 4
AU - Australia 4
IR - Iran 4
JM - Giamaica 4
LK - Sri Lanka 4
PY - Paraguay 4
UA - Ucraina 4
AZ - Azerbaigian 3
KG - Kirghizistan 3
LV - Lettonia 3
SA - Arabia Saudita 3
TH - Thailandia 3
TN - Tunisia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
BH - Bahrain 2
CO - Colombia 2
GE - Georgia 2
GR - Grecia 2
HR - Croazia 2
KE - Kenya 2
KR - Corea 2
KZ - Kazakistan 2
PE - Perù 2
RO - Romania 2
AM - Armenia 1
BO - Bolivia 1
BZ - Belize 1
CG - Congo 1
CM - Camerun 1
CR - Costa Rica 1
CU - Cuba 1
DM - Dominica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
GY - Guiana 1
JO - Giordania 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
MM - Myanmar 1
MN - Mongolia 1
MZ - Mozambico 1
NO - Norvegia 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
PH - Filippine 1
PS - Palestinian Territory 1
PT - Portogallo 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TM - Turkmenistan 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 5.680
Salva come PNG Salva come JPEG
Città #
Dallas 404
Hong Kong 317
Singapore 256
Ashburn 237
Dublin 203
Beijing 195
Chandler 175
New York 137
Munich 131
Boardman 97
Los Angeles 91
Helsinki 82
Shanghai 66
Redondo Beach 63
Milan 60
Moscow 53
Turku 49
Seattle 40
Pavia 35
Princeton 32
Ho Chi Minh City 31
Warsaw 30
Tokyo 29
Lawrence 27
The Dalles 26
Buffalo 24
Hanoi 24
Orem 24
Denver 22
Medford 22
São Paulo 21
Poplar 19
Brooklyn 18
Toronto 18
Frankfurt am Main 17
Wilmington 17
Atlanta 15
Boston 15
London 15
Chicago 14
Düsseldorf 14
Johannesburg 14
Phoenix 14
Rome 14
Columbus 13
Stockholm 13
San Francisco 12
Ankara 11
Montreal 11
Nuremberg 11
Santa Clara 11
Washington 11
Chennai 10
Falkenstein 10
Houston 10
Amsterdam 9
Lauterbourg 9
Mexico City 9
Charlotte 8
Lecce 8
Belo Horizonte 7
Brussels 7
Mumbai 7
Piscataway 7
Querétaro 7
Haiphong 6
Jinan 6
Nanjing 6
Xi'an 6
Biên Hòa 5
Guangzhou 5
Hyderabad 5
Jakarta 5
Manchester 5
Paris 5
Porto Alegre 5
Portsmouth 5
Pune 5
Ann Arbor 4
Baghdad 4
Bergamo 4
Cairo 4
Colombo 4
Corsico 4
Da Nang 4
Elk Grove Village 4
Fairfield 4
Menlo Park 4
Norwalk 4
Rio de Janeiro 4
Salvador 4
Santiago 4
Shenyang 4
Uberlândia 4
Zhengzhou 4
Baku 3
Betim 3
Boves 3
Bovisio Masciago 3
Brasília 3
Totale 3.560
Salva come PNG Salva come JPEG
Nome #
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study 123
Low risk for SARS-CoV2 symptomatic infection and early complications in paediatric patients during the ongoing CoVID19 epidemics in Lombardy 119
Low risk for SARS-CoV2 symptomatic infection and early complications in paediatric patients during the ongoing CoVID19 epidemics in Lombardy 108
EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count 108
Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis 103
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up 102
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study 93
SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers 91
Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice 90
Impact of immunosuppressive treatment on the immunogenicity of mRNA Covid-19 vaccine in vulnerable patients with giant cell arteritis 88
Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection- A retrospective observational case-controlled study 87
Characterization of varicella-zoster (Vzv) specific t cell response in healthy subjects and transplanted patients by using enzyme linked immunospot (elispot) assays 87
19n01, a Broadly Neutralizing Antibody Against Omicron BA.1, BA.2, BA.4/5, and Other SARS-CoV-2 Variants of Concern 86
Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020 85
Human Cytomegalovirus-Specific Memory CD4+T-Cell Response and Its Correlation with Virus Transmission to the Fetus in Pregnant Women with Primary Infection 84
Characterization of immune response against monkeypox virus in cohorts of infected patients, historic and newly vaccinated subjects 83
Dengue Virus-Specific Humoral and T Cellular Immune Response in Italian Residents and Travelers Returning from Endemic Areas 81
Detection of the SARS-CoV-2 in different biologic specimens from positive patients with COVID-19, in Northern Italy 78
Authors' response: COVID-19: how accurate are seroprevalence studies? 75
Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study 74
Evaluation of EBV- and HCMV-Specific T Cell Responses in Systemic Lupus Erythematosus (SLE) Patients Using a Normalized Enzyme-Linked Immunospot (ELISPOT) Assay 73
Differential Kinetics of Effector and Memory Responses Induced by Three Doses of SARS-CoV-2 mRNA Vaccine in a Cohort of Healthcare Workers 72
CD4 T Cell Determinants in West Nile Virus Disease and Asymptomatic Infection 72
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study 72
Sars-cov-2 virologic and immunologic correlates in patients with olfactory and taste disorders 68
Dynamics of humoral and cellular immunity elicited by the BNT162b2 mRNA vaccine in psoriatic patients under targeted immunosuppression: A longitudinal cohort study 67
Immunity to SARS-CoV-2 up to 15 months after infection 64
Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in ∼40% of patients 64
Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department 64
Machine Learning-based Voice Assessment for the Detection of Positive and Recovered COVID-19 Patients 64
Macrophages and monocytes: “trojan horses” in covid-19 63
EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count 63
Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection 63
Outbreak of measles genotype H1 in Northern Italy originated from a case imported from Southeast Asia, 2017 63
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up 62
Immunological Aspects of Human Papilloma Virus-Related Cancers Always Says, "I Am like a Box of Complexity, You Never Know What You Are Gonna Get" 61
Asymptomatic infection with clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) in carnivore pets, Italy, April 2023 60
Association between Vitamin D Serum Levels and Immune Response to the BNT162b2 Vaccine for SARS-CoV-2 60
Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment 59
ELISPOT assays with pp65 peptides or whole HCMV antigen are reliable predictors of immune control of HCMV infection in seropositive kidney transplant recipients 59
Immunological Aspects of Human Papilloma Virus-Related Cancers Always Says, “I Am like a Box of Complexity, You Never Know What You Are Gonna Get” 59
Human Cytomegalovirus (HCMV) - specific T-cell response after letermovir prophylaxis is predictive for subsequent HCMV reactivation in haematopoietic stem cell transplant recipients 59
SARS-CoV-2 positivity in rectal swabs: implication for possible transmission 59
Adenovirus-vectored SARS-CoV-2 vaccine expressing S1-N fusion protein 59
Adapting Neutralizing Antibodies to Viral Variants by Structure-Guided Affinity Maturation Using Phage Display Technology 58
Effect of a Third Dose of SARS-CoV-2 mRNA BNT162b2 Vaccine on Humoral and Cellular Responses and Serum Anti-HLA Antibodies in Kidney Transplant Recipients 58
The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy 58
Clinical, virological and immunological evolution of the olfactory and gustatory dysfunction in COVID-19 57
Deep learning and machine learning-based voice analysis for the detection of COVID-19: A proposal and comparison of architectures 57
Immunosuppressive treatments selectively affect the humoral and cellular response to SARS-CoV-2 in vaccinated patients with vasculitis 57
Zika virus infection in pregnancy: Advanced diagnostic approaches in dengue-naive and dengue-experienced pregnant women and possible implication for cross-reactivity and cross-protection 57
Herpes zoster in patients with solid tumors treated with immune checkpoint inhibitors 57
Human Cytomegalovirus and Epstein-Barr virus specific immunity in patients with ulcerative colitis 55
Conversion of monoclonal IgG to dimeric and secretory IgA restores neutralizing ability and prevents infection of Omicron lineages 55
Performance of new pp65-IGRA for the quantification of HCMV-specific CD4+ T-cell response in healthy subjects and in solid organ transplant recipients 55
SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay 54
A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice 52
Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up 52
mRNA BNT162b Vaccine Elicited Higher Antibody and CD4+ T-Cell Responses than Patients with Mild COVID-19 52
The 'hit-and-run' strategy and viral carcinogenesis 51
Evaluation of the Neutralizing Antibodies Response against 14 SARS-CoV-2 Variants in BNT162b2 Vaccinated Naïve and COVID-19 Positive Healthcare Workers from a Northern Italian Hospital 51
Both SARS-CoV-2 infection and vaccination in pregnancy elicited neutralizing antibodies in pregnant women and newborns 50
Corrigendum to "Seroprevalence of SARS-CoV-2 in 1922 blood donors from the Lodi Red Zone and adjacent Lodi metropolitan and suburban area" [Clin Microbiol Infect 27 (6) (2021 Jun) 914.e1-914.e4] 49
Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment 49
Characterization of CCP: Can We Use Past Convalescent Plasma from COVID-19 Patients for Treatment of New Emerging Variants? 48
Seroprevalence of SARS-CoV-2 in blood donors from the Lodi Red Zone and adjacent Lodi metropolitan and suburban area 48
Infectious complications and immunotherapy: old pitfalls and new horizons 48
Immune Control of Human Cytomegalovirus (HCMV) Infection in HCMV-Seropositive Solid Organ Transplant Recipients: The Predictive Role of Different Immunological Assays 46
Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant 46
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern 46
Long-term dynamics of natural killer cells in response to SARS-CoV-2 vaccination: Persistently enhanced activity postvaccination 46
Auto-Abs neutralizing type I IFNs in patients with severe Powassan, Usutu, or Ross River virus disease 44
SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice 44
The 2023 dengue outbreak in Lombardy, Italy: A one-health perspective 44
Human Cytomegalovirus Virion‐Associated mRNA as a Marker of Productive Infection in Immunocompromised Patients 43
Serum and breastmilk SARS-CoV-2 specific antibodies following BNT162b2 vaccine: prolonged protection from SARS-CoV-2 in newborns and older children 42
SARS-CoV-2 variants inactivation of plasma units using a riboflavin and ultraviolet light-based photochemical treatment 41
Emergence of Letermovir-resistant HCMV UL56 mutant during rescue treatment in a liver transplant recipient with ganciclovir-resistant infection HCMV: a case report 41
Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit 41
High-throughput peptide array analysis and computational techniques for serological profiling of flavivirus infections: Implications for diagnostics and vaccine development 41
Photopheresis abates the anti-hla antibody titer and renal failure progression in chronic antibody-mediated rejection 41
Preliminary results on an autochthonous dengue outbreak in Lombardy Region, Italy, August 2023 40
Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection 40
Immune response to bnt162b2 in solid organ transplant recipients: Negative impact of mycophenolate and high responsiveness of sars-cov-2 recovered subjects against delta variant 40
Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit 37
West nile or usutu virus? A three-year follow-up of humoral and cellular response in a group of asymptomatic blood donors 37
null 37
Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) 36
Performance of Whole Blood Stimulation Assays for the Quantification of SARS-CoV-2 Specific T-Cell Response: A Cross-Sectional Study 35
Molecular Epidemiology of Rhinovirus/Enterovirus and Their Role on Cause Severe and Prolonged Infection in Hospitalized Patients 35
Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs 34
Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19 32
Vaccination for herpes zoster in patients with solid tumors: a position paper on the behalf of the Associazione Italiana di Oncologia Medica (AIOM) 31
Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report 29
Memory T cells specific for HBV enumerated by a peptide-based cultured enzyme-linked immunospot assay in healthy HBV-vaccinated subjects 29
SARS-CoV-2 viability on different surfaces after gaseous ozone treatment: a preliminary evaluation 28
Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant 21
Tetravalent SARS-CoV-2 S1 subunit protein vaccination elicits robust humoral and cellular immune responses in SIV-infected rhesus macaque controllers 17
Thirteen Years of Phleboviruses Circulation in Lombardy, a Northern Italy Region 17
Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection 16
Totale 5.799
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.926
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.926
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202117 0 0 0 0 0 1 1 7 5 0 3 0
2021/2022184 2 1 5 26 12 3 4 13 4 17 16 81
2022/2023618 42 51 4 48 31 38 6 17 278 12 79 12
2023/2024664 61 113 40 31 53 161 57 45 6 22 39 36
2024/20251.919 49 95 29 104 35 125 114 77 489 127 236 439
2025/20262.346 361 291 515 514 514 151 0 0 0 0 0 0
Totale 5.814